BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Keck Graduate Institute of Applied Life Sciences Professor Links MicroRNA Gene to Aggressive Skin Cancer


10/13/2011 12:44:31 PM

CLAREMONT, Calif., Oct. 13, 2011 /PRNewswire/ -- A certain microRNA gene, miR-34b, could be a useful biomarker in early diagnosis of the most lethal forms of melanoma, according to new research published by KGI Professor Animesh Ray and his research collaborators.

Ray, together with Dr. Ranjan Perera, an associate professor at the Sanford Burnham Medical Research Institute in Orlando, Florida, spent nearly five years identifying microRNA molecules (a kind of non-coding RNA recently implicated as important gene regulatory agents) and their genes, which could signal whether tumors may develop into aggressive cancers.

Their paper, "Epigenetic Regulation of MicroRNA Genes and the Role of miR-34b in Cell Invasion and Motility in Human Melanoma," was published recently in the scientific journal PLoS One.

"There are no good molecular markers that a physician can look at to determine whether a particular skin tumor is invasive or not," notes Ray, who serves as KGI's faculty chair as well as director of the PhD program and the Center for Network Studies. "After one develops an aggressive form of melanoma, which metastasizes in different tissues, there is no targeted chemotherapy."

Melanoma, the most serious type of skin cancer, accounted for nearly 70,000 cases of skin cancer last year and most of the nearly 12,000 deaths, according to the American Cancer Society. Melanoma has complex origins, influenced by genetic predisposition, prolonged exposure to ultraviolet rays of the sun and the extent of melanin pigmentation of the skin.

Perera and Ray evaluated, at a molecular level, the difference between normal skin cells and cancer skin cells. They also analyzed the different properties of cell lines taken from a skin cancer patient's primary tumor and lymph glands, where the invasive cancer had spread.

Ray has received funding from the National Science Foundation and the National Institutes of Health, while Perera secured funding from the Sanford Burnham Medical Research Institute.

Further research would involve identifying additional microRNA genes related to melanoma. In highly controlled experiments, the researchers would implant human melanoma cells into specially manufactured mouse strains to determine if they could alter the microRNA genes to reverse aggressive melanoma, Ray says.

SOURCE Keck Graduate Institute


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->